SENTARA HEALTH PLANS

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-668-1550</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

<u>For Medicare Members:</u> Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. Additional indications may be covered at the discretion of the health plan.

<u>Drug Requested</u>: Xerava[™] (eravacycline) IV (J0122) (Medical)

MEMBER & PRESCRIBER INF	ORMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
Phone Number:	Fax Number:
NPI #:	
DRUG INFORMATION: Authoriz	ation may be delayed if incomplete.
Drug Form/Strength:	
Dosing Schedule:	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight (if applicable):	Date weight obtained:
	, the timeframe does not jeopardize the life or health of the member of function and would not subject the member to severe pain.
	low all that apply. All criteria must be met for approval. To ion, including lab results, diagnostics, and/or chart notes, must be
Length of Authorization: Date of	Service (14 days)
□ New Start	
☐ Member is 18 years of age or older	

(Continued on next page)

☐ Member has a diagnosis of complicated intra-abdominal infection (cIAI) with limited or no alternative

treatment options

	Provider has submitted lab cultures from current hospital admission or office visit collected within the last 7 days	
	Lab cultures must show that bacteria is sensitive to Xerava	
	Member must meet ONE of the following:	
	Provider must submit chart notes documenting trial and failure of <u>ALL</u> the following IV antibiotics: ciprofloxacin, levofloxacin, ceftriaxone, cefazolin, cefepime, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, ertapenem, imipenem-cilastatin, and meropenem	
	Cultures (retrieved from most recent office visit or current inpatient admission collected within the last 7 days) shows resistance to <u>ALL</u> the following IV antibiotics: ciprofloxacin, levofloxacin, ceftriaxone, cefazolin, cefepime, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, ertapenem, imipenem-cilastatin, and meropenem	
Len	gth of Authorization: Date of Service	
- (Continuation of therapy following inpatient administration	
	Member is currently on Xerava for more than 72 hours inpatient (progress notes must be submitted)	
□ Provider has submitted lab culture sensitivity results retrieved during inpatient admission which shows resistance to <u>ALL</u> preferred antibiotics except for Xerava (sensitive)		
Med	dication being provided by: Please check applicable box below.	
	Location/site of drug administration:	
]	NPI or DEA # of administering location:	
	<u>OR</u>	
□ Specialty Pharmacy		
Г		

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *